Triomics
Triomics builds OncoLLM, an oncology-tuned generative AI platform that automates clinical trial matching, visit preparation, and cancer registry abstraction for NCI-designated cancer centers, community oncology practices, and pharmaceutical sponsors.
- Company typePrivate
- Founded2021
- HeadquartersSan Francisco, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Triomics does
Triomics is a privately held, New York–headquartered generative AI company founded in 2021 by Sarim Khan (CEO) and Hrituraj Singh (CTO) that builds oncology-specific AI infrastructure to convert unstructured cancer records into structured, cited, auditable intelligence. Its core technology, OncoLLM, is a proprietary constellation of eight specialized large language models ranging from 3B to 72B parameters, paired with the OncoIndexer ingestion pipeline that normalizes HL7, FHIR, CCDA, XML, PDF, TIFF, and JPEG inputs from Epic, OncoEMR, iKnowMed, and Cerner into LLM-ready data, enabling patient-level reasoning across the full longitudinal record (notes, pathology, imaging, molecular, scanned faxes). Triomics packages this platform as three workflow modules: PRISM for clinical trial matching, Symphony for visit preparation and pre-charting, and Harmony for cancer registry curation and structured data abstraction against NAACCR, CoC, and QOPI dictionaries. The platform's accuracy has been peer-reviewed in Nature Digital Medicine and presented at the ASCO 2025 Annual Meeting and Quality Care Symposium, with reported outcomes of 95% extraction and trial match accuracy, a 40% increase in trial matches, more than 30% increase in enrollments, and a 67% reduction in manual chart review time.
The company sells primarily through enterprise SaaS contracts with cancer centers and life-sciences organizations, supplemented by forward-deployed implementation and professional services, with custom quote-based pricing, no public list prices, and 30-minute demo sessions gated by BAAs for customer data. It serves three primary customer segments: NCI-designated academic cancer centers (4 of the top 10 U.S. cancer centers and 10+ NCI-designated centers are deployed, including MSK, MD Anderson, Yale/Smilow, Mount Sinai, and IU Health), large community oncology networks (Texas Oncology), and pharmaceutical/life-sciences sponsors (Eli Lilly, with deployment at investigator sites for enrollment, feasibility, and protocol design). The company is venture-backed, with a $15M Series A in May 2024 and a $22M Series B in May 2026 led by Battery Ventures, bringing total disclosed funding to over $36M; reported metrics include a 10x year-over-year increase in ARR and a 4x expansion of enterprise customers alongside platform-wide processing of 1,000,000+ medical records and screening of 65,000+ patients for trials per month.
Triomics firmographics
Firmographics- Name
- Triomics
- Legal name
- Triomics Inc.
- Website
- https://triomics.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Triomics builds OncoLLM, an oncology-tuned generative AI platform that automates clinical trial matching, visit preparation, and cancer registry abstraction for NCI-designated cancer centers, community oncology practices, and pharmaceutical sponsors.
- Ownership category
- akta.pro rank
Triomics industry classification
Industry- Product category
- Oncology clinical AI software
- NAICS
- Computer Systems Design and Related Services (54151), Software Publishers (5132), Computer Systems Design Services (541512)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370), Services-Computer Integrated Systems Design (7373), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)
- akta.pro secondary industries
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Clinical & Claims Data Integration for Population Health (payer-provider data fusion) (HLACAHAI), Data Access, Sharing & Marketplace Platforms (incl. TEFCA/QHIN enablement) (HLACAIAL)
Keywords
Where Triomics is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Triomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Revenue model
- Enterprise SaaS subscriptions (implied): Triomics deploys its PRISM, Symphony, and Harmony platforms into cancer centers and life-sciences organizations under multi-year contracts. TechCrunch reports a 10-fold increase in annualized recurring revenue over the prior year, indicating a recurring SaaS revenue model. Customer contracts are site-governed under HIPAA, IRB, and CTA requirements.
- Life sciences / sponsor services: Sponsor-facing capabilities (accelerated enrollment, screening throughput visibility, precise feasibility, trial design optimization) packaged for pharma/biotech sponsors using Triomics deployments at investigator sites; outputs governed by site-approved data-sharing.
- Deployment and implementation services (implied): Forward-deployed engineering teams are explicitly being expanded with the Series B, supporting deployment, integration, and ongoing implementation for enterprise customers — indicative of professional services revenue bundled with the platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Quote-based enterprise contracts for PRISM, Symphony, and Harmony deployments |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Triomics product offering
Product offeringCore offering
Triomics builds an oncology-specialized generative AI platform that automates clinical trial matching, pre-visit charting, and cancer registry abstraction for cancer centers, oncology practices, and life sciences sponsors. The platform combines a proprietary suite of fine-tuned large language models (OncoLLM) with a unified EHR ingestion pipeline (OncoIndexer) to surface eligible patients and streamline oncology workflows. It is sold as enterprise software to provider organizations and as solutions to pharma sponsors for patient identification and cohort analytics.
Product overview
Triomics offers a single unified AI platform — OncoLLM — packaged as a constellation of eight specialized large language models (3B to 72B parameters) that reason at the patient level across the full longitudinal oncology record, with three named workflow modules built on top: PRISM for clinical trial matching, Symphony for visit preparation and pre-charting, and Harmony for registry-ready structured data abstraction. The platform is delivered through two solution suites — a Cancer Centers suite for providers and a Life Sciences suite for sponsors — supported by the OncoIndexer ingestion pipeline that normalizes HL7, FHIR, CCDA, XML, PDF, TIFF, and JPEG data from EMR systems including Epic, OncoEMR, iKnowMed, and Cerner.
Differentiator
Problem solved
Functional benefit
Brands
- PRISM: AI-powered clinical trial matching platform that screens every upcoming patient against every active trial and produces cited, prioritized worklists (Patient Records Interpretation for Semantic clinical trial Matching system).
- Symphony
- Harmony
- OncoLLM
Products and services
- OncoLLM Oncology-specialized large language model suite comprising eight fine-tuned models that power Triomics' clinical workflows; used internally as the AI foundation for all customer-facing products.
- OncoIndexer Data ingestion and normalization pipeline that processes structured and unstructured EHR and oncology data and feeds it into OncoLLM and downstream products.
- PRISM Clinical trial matching and eligibility-screening product that identifies oncology patients eligible for relevant trials using OncoLLM; sold to cancer centers, practices, and life sciences sponsors.
- Symphony Pre-charting and visit-preparation product that uses OncoLLM to assemble oncology visit notes and documentation ahead of patient appointments.
- Harmony Cancer registry abstraction and reporting product that uses OncoLLM to extract structured registry data from oncology records for cancer program reporting.
- Cancer Centers Platform Provider-facing solution bundle of Triomics' products (PRISM, Symphony, Harmony) sold to cancer centers and oncology practices for trial matching, pre-charting, and registry abstraction.
- Life Sciences Solutions Sponsor-facing solution offering patient identification, cohort analytics, and real-world oncology data generation for pharmaceutical, biotech, and clinical research customers.
Quantifiable outcome
- 95% accuracy in PRISM patient-to-trial matching
- +7 more outcomes
Companies that use Triomics
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
Triomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability10 records
Feature7 records
Triomics partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core research partner, core research sponsor partner, flagship customer / flagship partner, core technology partner, core ehr integration partner, core oncology ehr integration partner and flagship community oncology partner and investor affiliate.
- Regenstrief Institutecore research partnerSponsor-funded hybrid effectiveness-implementation study to evaluate Triomics PRISM with IU Health Oncology; Dr. Jiang Bian leads technical audit and Dr. David Haggstrom leads implementation evaluation.
- IU Health Oncologycore research partnerTriomics PRISM is being evaluated across two IU Health oncology satellite sites in a hybrid effectiveness-implementation study with Regenstrief and Eli Lilly.
- Eli Lilly and Companycore research sponsor partnerSponsor of the Triomics PRISM hybrid effectiveness-implementation study with IU Health and Regenstrief; collaboration funded to evaluate AI-enabled clinical trial screening in real oncology workflows.
- Mount Sinai Tisch Cancer Centerflagship customer / flagship partnerLaunched PRISM (powered by Triomics' OncoLLM) for systemwide clinical trial matching across the Mount Sinai Health System; first NCI-designated Comprehensive Cancer Center in NYC to deploy oncology-specific AI for systemwide matching.
- Yale Cancer Center / Smilow Cancer Hospitalflagship customer / flagship partnerExpanded use of Triomics' AI-powered clinical-trial screening at Yale Cancer Center and Smilow Cancer Hospital in Connecticut; PRISM pre-screens 100% of patient visits against all active trials.
- Savistacore technology partnerSavista partners with Triomics to launch the industry's first automated, full-stack cancer registry solution, combining Savista's registry expertise with Triomics' OncoLLM-based abstraction.
- Memorial Sloan Kettering Cancer Center (MSK)flagship customer / flagship partnerTriomics announced a collaboration with MSK to deploy its AI-powered clinical trial matching system, including expansion across MSK's clinical trial portfolio and decentralized trials in satellite clinics.
- Epic Systemscore ehr integration partnerNative integration with Epic; PRISM is approved on the Epic App Marketplace. Outputs land in Epic in-baskets, worklists, and EHR notes.
- OncoEMRcore oncology ehr integration partnerNative integration with OncoEMR alongside Epic and iKnowMed.
- iKnowMedcore oncology ehr integration partnerNative integration with iKnowMed (used by community oncology practices such as US Oncology Network).
- Cernercore ehr integration partnerListed alongside Epic, OncoEMR as a native EMR integration supported by Triomics PRISM.
- Texas Oncology (Precision Health Informatics)flagship community oncology partner and investor affiliateTriomics is working with Texas Oncology, one of the nation's largest community oncology practices; Precision Health Informatics (a Texas Oncology subsidiary) is both a strategic investor in the Series B and a customer channel.
Scale indicators15 records
Recent moves6 records
Expansion highlights6 records
Triomics competitors and assessment
Company assessmentDirect peers
- Deep 6 AI: AI-driven patient recruitment and clinical-trial matching platform that mines EHR data to identify eligible patients. Directly comparable to Triomics PRISM in target use case (patient-to-trial matching), customer base (health systems and sponsors), and underlying technology (EHR-mining AI).
- Mendel: Generative-AI platform for structuring unstructured clinical text and surfacing patients for clinical trials and research cohorts. Closely comparable to Triomics OncoLLM in core technology and to PRISM in trial matching, with overlapping buyers in life sciences and academic medical centers.
- Massive Bio: AI-powered oncology clinical trial matching and enrollment service for cancer patients and sponsors. Directly comparable to Triomics PRISM in oncology-specific trial matching, with overlap in pharma-sponsor go-to-market.
- Trial Library: Oncology-specific clinical trial search and matching platform used by cancer centers and sponsors. Comparable to PRISM in oncology trial matching and to Triomics' cancer-center go-to-market.
Broad incumbents
- Flatiron Health: Roche-owned oncology-specific EHR, real-world data, and AI platform for cancer centers and life-sciences sponsors. A larger incumbent in the same oncology AI/data space that Triomics addresses with OncoLLM, PRISM, and Harmony.
- Tempus: Public precision-medicine and AI company combining molecular profiling, oncology data, and clinical AI for providers and pharma. Broad incumbent competing with Triomics across oncology data, AI insights, and pharma services.
- ConcertAI: Oncology real-world data and AI SaaS for providers, payers, and life-sciences sponsors. Comparable to Triomics in oncology data abstraction (Harmony) and life-sciences offerings.
- Syapse: Oncology real-world evidence and decision-support platform for providers and pharma. Comparable to Triomics in oncology-specific data curation and life-sciences analytics.
- IQVIA (E360 / Patient Finder): Global clinical research and data powerhouse with AI-enabled trial matching and feasibility offerings (e.g., E360). Broad incumbent competing with Triomics' life-sciences/sponsor side and with the scale to bundle trial-matching into enterprise contracts.
Emerging players
- Atropos Health: AI platform for real-world evidence generation from EHR data, used by health systems and life sciences. Emerging peer with partial overlap in AI-driven oncology insights and life-sciences evidence generation.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Triomics social profiles
Digital presenceTriomics compliance and trust
Trust signalCompliance5 records
Triomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Triomics leadership team
Management profileNumber of profiles
Profiles3 records
Triomics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Triomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Triomics
What does Triomics do?
Triomics builds an oncology-specialized generative AI platform that automates clinical trial matching, pre-visit charting, and cancer registry abstraction for cancer centers, oncology practices, and life sciences sponsors. The platform combines a proprietary suite of fine-tuned large language models (OncoLLM) with a unified EHR ingestion pipeline (OncoIndexer) to surface eligible patients and streamline oncology workflows. It is sold as enterprise software to provider organizations and as solutions to pharma sponsors for patient identification and cohort analytics.
Is Triomics a public or private company?
Triomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Triomics founded?
Triomics was founded in 2021. It employs 51 to 100 people.
Where is Triomics based?
Triomics is headquartered in San Francisco, United States, in the North America region.
How does Triomics make money?
Three revenue lines are on record. Enterprise SaaS subscriptions (implied) is the primary driver. The others are life sciences / sponsor services and deployment and implementation services (implied).
Who are Triomics's main competitors?
Direct peers on record are Deep 6 AI, Mendel, Massive Bio and Trial Library. Broad incumbents are Flatiron Health, Tempus, ConcertAI, Syapse and IQVIA (E360 / Patient Finder). Atropos Health is listed as an emerging player.
Does Triomics have an API?
No public API is recorded for Triomics.
What industry is Triomics in?
Triomics's product category is Oncology clinical AI software. Its primary akta.pro industry code is HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation, with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 54151 and its SIC code is 7370.